United-Guardian 3Q 2026: Revenue $3.49M, EPS $0.2 — 10-Q Summary
閱讀少於1分鐘
United-Guardian's revenue rose 54% and earnings increased year over year, with sales gains across pharmaceuticals, cosmetic ingredients and medical lubricants. Renacidin formulary coverage contributed to pharmaceutical growth, while increased purchases by ASI after its 2025 overstock situation drove cosmetic ingredient sales.
Financial Highlights
| Metric | Current quarter | Prior year quarter | YoY change |
| Revenue¹ | $3.49M | $2.26M | 54.3% |
| Net income² | $930.91K | $268.44K | 246.8% |
| Diluted EPS³ | $0.2 | $0.06 | 233.3% |
¹ Reported as “Net sales”. ² Reported as “Net income”. ³ Reported as “Earnings per common share (Basic and Diluted)”.
Business Highlights
- Pharmaceuticals: Net sales rose 29%; Renacidin formulary coverage and higher Clorpactin WCS-90 orders contributed to the increase.
- Cosmetic ingredients: Sales climbed 187%, primarily as ASI resumed regular purchases following its 2025 overstock situation.
- Medical lubricants: Sales increased 20%, driven by higher orders from a large customer in India.
- Cost of sales: Fell to 46% of sales from 58%, reflecting lower per-unit overhead costs from increased production.
Original SEC Filing: UNITED GUARDIAN INC [ UG ] - 10-Q - Nov. 12, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.